CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 170 filers reported holding CLOVIS ONCOLOGY INC in Q4 2018. The put-call ratio across all filers is 0.47 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2019 | $561,000 | -70.0% | 37,700 | -50.0% | 0.02% | -69.7% |
Q1 2019 | $1,871,000 | +38.2% | 75,400 | 0.0% | 0.08% | +31.0% |
Q4 2018 | $1,354,000 | -38.8% | 75,400 | 0.0% | 0.06% | -27.5% |
Q3 2018 | $2,214,000 | -35.4% | 75,400 | 0.0% | 0.08% | -38.5% |
Q2 2018 | $3,428,000 | -13.9% | 75,400 | 0.0% | 0.13% | -16.1% |
Q1 2018 | $3,981,000 | -22.4% | 75,400 | 0.0% | 0.16% | -21.7% |
Q4 2017 | $5,127,000 | -17.5% | 75,400 | 0.0% | 0.20% | -10.8% |
Q3 2017 | $6,213,000 | -56.0% | 75,400 | -50.0% | 0.22% | -57.6% |
Q2 2017 | $14,119,000 | +470533.3% | 150,800 | +295586.3% | 0.52% | – |
Q4 2014 | $3,000 | -99.9% | 51 | -100.0% | 0.00% | -100.0% |
Q3 2014 | $4,720,000 | +140.7% | 104,051 | +119.7% | 0.22% | +22.8% |
Q2 2014 | $1,961,000 | -40.2% | 47,364 | 0.0% | 0.18% | -45.1% |
Q1 2014 | $3,281,000 | +66.7% | 47,364 | +45.0% | 0.33% | +58.5% |
Q4 2013 | $1,968,000 | +42.7% | 32,658 | +44.0% | 0.21% | +35.3% |
Q3 2013 | $1,379,000 | – | 22,687 | – | 0.15% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 814,833 | $60,485,054,000 | 53.20% |
Palo Alto Investors LP | 2,121,857 | $157,505,000 | 7.79% |
NEA Management Company, LLC | 2,279,781 | $169,228,000 | 7.65% |
EcoR1 Capital, LLC | 243,048 | $18,041,000 | 6.01% |
Redmile Group, LLC | 900,879 | $66,872,000 | 6.00% |
Opaleye Management Inc. | 140,000 | $10,392,000 | 4.82% |
PFM Health Sciences, LP | 2,266,756 | $168,261,000 | 4.64% |
Partner Investment Management, L.P. | 40,798 | $3,028,000 | 4.56% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 826,919 | $61,383,000 | 3.74% |
Opus Point Partners Management, LLC | 55,988 | $4,156,000 | 3.48% |